HitGen Inc.

Industry

  • Biotechnology
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • Molecular Diversity
    • Antisense, Oligonucleotides
  • Pharmaceuticals
    • Specialty Pharmaceuticals
    • Vaccines
  • Distributors
  • Contract Research Organization-CRO

Other Names/Subsidiaries

  • HitGen Pharmaceuticals
  • Vernalis (R&D)
See more in Biomedtracker

Latest on HitGen Inc.

Scrip

Chinese Cell And Gene Therapies Enjoy Limelight Amid Summer Fundraising Lull

 
• By Dexter Jie Yan

Chinese developers of cell and gene therapies continued to enjoy the limelight in July and August, although a summer lull set in for fundraisings backed by venture capital and private equity firms. Co

Scrip

Deal Watch: Lilly Turns To Oblique For Antibody Discovery

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Lilly Teams With Oblique On Antibody Di

Scrip

Deal Watch: AbbVie Adds To Immunology Pipeline Through Deal With OSE

 
• By Joseph Haas, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. AbbVie To Pay $48m Up Front For Preclin

Scrip

Novartis Bags Chong Kun Dang’s HDAC6 Inhibitor In $1.3bn Deal

 
• By Jung Won Shin

Novartis AG has reached an agreement for exclusive global (excluding South Korea) development and commercialization rights to Chong Kun Dang Pharmaceutical Corp. 's (CKD) CKD-510, a selective, non-h